September 17, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Company
News Sectors
Automotive
Communications
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Research
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
News Alerts
News Search
Photo Gallery
Company Login
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
 
 
Suprema Provides Palm-print Live Scanners to Poland & Lithuania
Suprema Provides Palm-print Live Scanners to Poland & Lithuania
Seoul, Nov 23, 2010 - (ACN Newswire) - Suprema, Inc., a global leader in biometrics and ID solutions, announced today that the company's RealScan-F palm-print live scanner has been selected for the AFIS systems of the Polish National Police and Lithuania's Citizenship & Migration Affairs.   [ more... ]

 Headline News

Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Mitsui & Co. has invested in "KIFMEC specific purpose company" which has been established in order to lease a hospital building to Kobe International Frontier Medical Center ("KIFMEC"). more info >>
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Yokogawa Electric announced that its confocal image single-cell drug discovery support system has been selected for the Japan Science and Technology Agency's (JST) next-generation technology transfer program (NexTEP). more info >>
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Sysmex Corporation and Toppan Printing Co., Ltd. are to cooperate for the advancement in the genetic analysis testing industry, and to invest in RIKEN GENESIS Co., Ltd., a Toppan Printing subsidiary. more info >>
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Takara Bio Inc. has submitted an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) dated April 30, 2014 in order to conduct a phase II clinical trial in the United States of the oncolytic virus HF10 in patients with unresected or metastatic malignant melanoma. more info >>
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Nitto Denko Corporation has been developing a new RNAi based drug for treating fibrosis in liver and other organs since 2008 in collaboration with Prof. Yoshiro Niitsu of Sapporo Medical University. more info >>
ACN Newswire
 Press Release News

Eisai to Present Latest Clinical Data on Halaven(R) (Eribulin) and Lenvatinib at 39th ESMO Congress (Sept 17, 2014)
Eisai Co., Ltd. announced today that a series of abstracts highlighting the latest clinical data on Halaven(R) and lenvatinib mesylate will be presented during the 39th European Society for Medical Oncology (ESMO) Congress 2014, taking place in Madrid, Spain, from September 26 - 30. more info >>
Eisai Enters Two Joint Research Agreements to Develop New Antimalarial Medicines (Sept 16, 2014)
Eisai Co., Ltd. announced today that it has entered into two joint research agreements for the development of new antimalarial medicines.
more info >>

Eisai and Kyorin Enter Into Agreement Concerning Compound Library Use for the Development of New Antibacterial Agents (Sept 11, 2014)
Eisai Co., Ltd. and Kyorin Pharmaceutical Co., Ltd., a wholly-owned subsidiary of KYORIN Holdings, Inc. announced today that they have entered into an agreement concerning the evaluation and use of Eisai's compound library, which includes natural products, by Kyorin with the aim of leveraging both companies' resources for the discovery of innovative new antibacterial agents.
more info >>

Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S. (Aug 20, 2014)
Eisai Co., Ltd. announced today that it has submitted applications to regulatory authorities in the U.S. and Europe (the FDA and EMA respectively) for the indication expansion of its in-house developed antiepileptic drug Fycompa as an adjunctive treatment of primary generalized tonic-clonic seizures (PGTC). more info >>
Eisai and Zeria Conclude License Agreement Concerning a New Portion Pump Inhibitor in Japan (Aug 18, 2014)
Eisai Co., Ltd. and Zeria Pharmaceutical Co., Ltd. announced today that they have concluded a license agreement concerning E3710, a novel proton pump inhibitor (PPI) discovered and developed in-house by Eisai. more info >>
 Global Press Release

Eisai to Present Latest Clinical Data on Halaven(R) (Eribulin) and Lenvatinib at 39th ESMO Congress (Sept 17, 2014)

Eisai Enters Two Joint Research Agreements to Develop New Antimalarial Medicines (Sept 16, 2014)

Zebrafish Genes Linked to Human Respiratory Diseases (Sept 15, 2014)

Eisai and Kyorin Enter Into Agreement Concerning Compound Library Use for the Development of New Antibacterial Agents (Sept 11, 2014)

Singaporean Birth Cohort Study Finds Benefits for Babies Exposed to Two Languages (Sept 2, 2014)

JCN Network - Company Profiles - Company Listing
 
CSR Report Download
Most Popular
About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)